Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting

• Status: Completed
• Trial end date: 2012-08-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to prove that at a dose of 1 mg Haloperidol possesses a high success rate in controlling established postoperative nausea and vomiting (PONV) in the first 24 hours following administration similar to the standard of care ondansetron 4 mg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: American University of Beirut Medical Center
• Treatments: Haloperidol; Haloperidol decanoate; Ondansetron

Criteria

Inclusion Criteria:

• Patients aged 18-80

• ASA class I, II, and III

• undergoing elective surgery under general anesthesia

Exclusion Criteria:

• Patients with history of arrhythmias, QTc prolongation or allergies to the study drugs will be excluded from the study.